Cargando…
Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials
Background. Efficacy of adding bevacizumab in first-line chemotherapy of metastatic colorectal cancer (mCRC) has been controversial. The aim of this study is to gather current data to analyze efficacy of adding bevacizumab to the most used combination first-line chemotherapy in mCRC, based on the 20...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058184/ https://www.ncbi.nlm.nih.gov/pubmed/24971091 http://dx.doi.org/10.1155/2014/594930 |
_version_ | 1782321089268940800 |
---|---|
author | Chen, Yan-xian Yang, Qiong Kuang, Jun-jie Chen, Shi-yu Wei, Ying Jiang, Zhi-min Xie, De-rong |
author_facet | Chen, Yan-xian Yang, Qiong Kuang, Jun-jie Chen, Shi-yu Wei, Ying Jiang, Zhi-min Xie, De-rong |
author_sort | Chen, Yan-xian |
collection | PubMed |
description | Background. Efficacy of adding bevacizumab in first-line chemotherapy of metastatic colorectal cancer (mCRC) has been controversial. The aim of this study is to gather current data to analyze efficacy of adding bevacizumab to the most used combination first-line chemotherapy in mCRC, based on the 2012 meta-analysis reported by Macedo et al. Methods. Medline, EMBASE and Cochrane library, meeting presentations and abstracts were searched. Eligible studies were randomized controlled trials (RCTs) which evaluated first-line chemotherapy with or without bevacizumab in mCRC. The extracting data were included and examined in the meta-analysis according to the type of chemotherapy regimen. Results. Seven trials, totaling 3436 patients, were analyzed. Compared with first-line chemothery alone, the adding of bevacizumab did not show clinical benefit for OS both in first-line therapy and the most used combination chemotherapy (HR = 0.89; 95% CI = 0.78–1.02; P = 0.08; HR = 0.93; 95% CI = 0.83–1.05; P = 0.24). In contrast with OS, the addition of bevacizumab resulted in significant improvement for PFS (HR = 0.68; 95% CI = 0.59–0.78; P < 0.00001). Moreover, it also demonstrated statistical benefit for PFS in the most used combination first-line chemotherapy (HR = 0.84; 95% CI = 0.75–0.94; P = 0.002). And the subgroup analysis indicated only capacitabine-based regimens were beneficial. Conclusions. This meta-analysis shows that the addition of bevacizumab to FOLFOX/FOLFIRI/XELOX regimens might not be beneficial in terms of OS. Benefit has been seen when PFS has been taken into account. In subgroup analysis, benefit adding bevacizumab has been seen when capecitabine-based regimens are used. Further studies are warranted to explore the combination with bevacizumab. |
format | Online Article Text |
id | pubmed-4058184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-40581842014-06-26 Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials Chen, Yan-xian Yang, Qiong Kuang, Jun-jie Chen, Shi-yu Wei, Ying Jiang, Zhi-min Xie, De-rong Gastroenterol Res Pract Review Article Background. Efficacy of adding bevacizumab in first-line chemotherapy of metastatic colorectal cancer (mCRC) has been controversial. The aim of this study is to gather current data to analyze efficacy of adding bevacizumab to the most used combination first-line chemotherapy in mCRC, based on the 2012 meta-analysis reported by Macedo et al. Methods. Medline, EMBASE and Cochrane library, meeting presentations and abstracts were searched. Eligible studies were randomized controlled trials (RCTs) which evaluated first-line chemotherapy with or without bevacizumab in mCRC. The extracting data were included and examined in the meta-analysis according to the type of chemotherapy regimen. Results. Seven trials, totaling 3436 patients, were analyzed. Compared with first-line chemothery alone, the adding of bevacizumab did not show clinical benefit for OS both in first-line therapy and the most used combination chemotherapy (HR = 0.89; 95% CI = 0.78–1.02; P = 0.08; HR = 0.93; 95% CI = 0.83–1.05; P = 0.24). In contrast with OS, the addition of bevacizumab resulted in significant improvement for PFS (HR = 0.68; 95% CI = 0.59–0.78; P < 0.00001). Moreover, it also demonstrated statistical benefit for PFS in the most used combination first-line chemotherapy (HR = 0.84; 95% CI = 0.75–0.94; P = 0.002). And the subgroup analysis indicated only capacitabine-based regimens were beneficial. Conclusions. This meta-analysis shows that the addition of bevacizumab to FOLFOX/FOLFIRI/XELOX regimens might not be beneficial in terms of OS. Benefit has been seen when PFS has been taken into account. In subgroup analysis, benefit adding bevacizumab has been seen when capecitabine-based regimens are used. Further studies are warranted to explore the combination with bevacizumab. Hindawi Publishing Corporation 2014 2014-05-25 /pmc/articles/PMC4058184/ /pubmed/24971091 http://dx.doi.org/10.1155/2014/594930 Text en Copyright © 2014 Yan-xian Chen et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Chen, Yan-xian Yang, Qiong Kuang, Jun-jie Chen, Shi-yu Wei, Ying Jiang, Zhi-min Xie, De-rong Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials |
title | Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials |
title_full | Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials |
title_fullStr | Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials |
title_full_unstemmed | Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials |
title_short | Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials |
title_sort | efficacy of adding bevacizumab in the first-line chemotherapy of metastatic colorectal cancer: evidence from seven randomized clinical trials |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058184/ https://www.ncbi.nlm.nih.gov/pubmed/24971091 http://dx.doi.org/10.1155/2014/594930 |
work_keys_str_mv | AT chenyanxian efficacyofaddingbevacizumabinthefirstlinechemotherapyofmetastaticcolorectalcancerevidencefromsevenrandomizedclinicaltrials AT yangqiong efficacyofaddingbevacizumabinthefirstlinechemotherapyofmetastaticcolorectalcancerevidencefromsevenrandomizedclinicaltrials AT kuangjunjie efficacyofaddingbevacizumabinthefirstlinechemotherapyofmetastaticcolorectalcancerevidencefromsevenrandomizedclinicaltrials AT chenshiyu efficacyofaddingbevacizumabinthefirstlinechemotherapyofmetastaticcolorectalcancerevidencefromsevenrandomizedclinicaltrials AT weiying efficacyofaddingbevacizumabinthefirstlinechemotherapyofmetastaticcolorectalcancerevidencefromsevenrandomizedclinicaltrials AT jiangzhimin efficacyofaddingbevacizumabinthefirstlinechemotherapyofmetastaticcolorectalcancerevidencefromsevenrandomizedclinicaltrials AT xiederong efficacyofaddingbevacizumabinthefirstlinechemotherapyofmetastaticcolorectalcancerevidencefromsevenrandomizedclinicaltrials |